Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960697 | 0.83 | CYP2D6 (0.39) | CYP2D6MEN1ALDH1A1KMT2ACHRNA7 | |
| SCHEMBL25081710 | 0.79 | CYP2D6 (0.37) | CYP2D6 | |
| SCHEMBL9963298 | 0.78 | CYP2D6 (0.36) | CYP2D6HRH3 | |
| SCHEMBL15960703 | 0.76 | KCNH2 (0.41) | CYP2D6HRH3 | |
| SCHEMBL12267734 | 0.76 | CYP2D6 (0.35) | CYP2D6HRH3 | |
| SCHEMBL24951670 | 0.76 | CYP2D6 (0.35) | CYP2D6HRH3 | |
| SCHEMBL15960718 | 0.75 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL22064017 | 0.74 | CYP2D6 (0.34) | CYP2D6MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL278248 | 0.73 | POLB (0.40) | CYP2D6ALDH1A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL12026662 | 0.73 | CYP2D6 (0.39) | CYP2D6MEN1ALDH1A1KMT2ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005769-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | STORCK PIERRE HENRI (GB) | 2013-01-03 | — | — | US | disclosed |
| US-20130005769-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | STORCK PIERRE HENRI (GB) | 2013-01-03 | — | — | US | disclosed |
| US-8288377-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-16 | — | — | US | disclosed |
| US-8288377-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-16 | — | — | US | disclosed |
| EP-2203447-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20100216770-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN-CILAG (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100216770-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN-CILAG (FR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009037343-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216770-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | CYP2D6 1222/4885MEN1 1788/4885ALDH1A1 3556/4885 |
| US-20130005769-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | CYP2D6 1222/4885MEN1 1788/4885ALDH1A1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.